Teijin Cordley Limited, the Teijin Frontier Group’s high-grade artificial leather business, announced today that it has developed a new antibacterial and antiviral (*1) artificial leather incorporating long-lasting antibacterial agent.
Teijin Cordley will commence sales of the new artificial leather in October this year; initial versions will be designed for the manufacture of children’s satchels; subsequent versions will additionally be suitable for sporting goods such as shoes and leather balls. The sales target is 30000 meetres in fiscal 2021 and 580,000 meters in fiscal 2024.
Leveraging Teijin Cordley’s unique surface treatment technology, the new antibacterial and antiviral artificial leather can be treated with the same process as conventional artificial leathers such as natural-like, enamel and nubuck artificial leathers, and can be used in a wide range of applications. In addition, products using the new leather material can be classified as “environmentally friendly”, as it is created using recycled polyester raw materials. The long-lasting antibacterial agent on new artificial leather’s surface has led it acquiring SIAA (*2) antibacterial processing and SIAA antiviral processing certification.
(*2) SIAA: The SIAA brand mark is borne on products under quality control and information disclosure by the guidelines of the Society of International sustaining growth for Antimicrobial Articles
The technology in the long-lasting antibacterial agent was originally developed to control the growth of microorganisms such as mold in the confined spaces of submarines, and is effective against various kinds of bacteria, mold and viruses. In addition, it has the potential to treat a variety of materials such as fibers and hard materials, and has been used in applications including apparel, rush products, and humidifying filters for air purifiers.
The spread of COVID-19 has enhanced general interest in infection control in daily life, and the need for antibacterial and antiviral processing is increasing. There is also increased focus on the need for hygiene measures during sporting events. Antibacterial and antiviral processing technology for general textile products has been developed for practical use; however, it is difficult to maintain the antibacterial and antiviral properties when these are processed into artificial leather.
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan’s first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions,” Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD 9.5 billion) in the fiscal year that ended on March 31, 2021.